---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-172958"
form_type: "8-K"
ticker: "SPRY"
cik: "0001671858"
company_name: "ARS Pharmaceuticals, Inc."
filed_at: "2022-06-13T23:59:59+00:00"
generated_at: "2026-06-25T02:23:49.365184+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# Silverback Therapeutics stockholders elect directors, ratify auditor at 2022 annual meeting

## Summary
- Andrew Powell and Peter Thompson were elected Class II directors to serve until 2025 annual meeting.
- Ernst & Young LLP was ratified as independent auditor for fiscal year ending Dec 31, 2022 with 99.8% of votes in favor.
- Approximately 35.1 million shares were outstanding and entitled to vote as of April 11, 2022 record date.

## SEC filing metadata
- accession: 0001193125-22-172958
- form_type: 8-K
- ticker: SPRY
- cik: 0001671858
- company_name: ARS Pharmaceuticals, Inc.
- filed_at: 2022-06-13T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671858/000119312522172958/0001193125-22-172958-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671858/000119312522172958/d352185d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-172958
- JSON: https://secwatch.observer/filing/0001193125-22-172958.json
- Plain text: https://secwatch.observer/filing/0001193125-22-172958.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.